糖尿病黄斑水肿（DME）是导致糖尿病患者视功能损伤的主要原因之一，DME的治疗方法包括激光光凝治疗、抗炎治疗和抗血管内皮生长因子（VEGF）治疗。近年来，抗VEGF药物Ranibizumab、Bevacizumab、VEGF-Trap和KH902等对DME有良好的治疗效果。文章对DME抗VEGF治疗进展进行综述，探讨抗VEGF治疗的有效性和安全性。

Diabetic macular edema (DME) is one of the major causes of visual impairment in patients with diabetes mellitus. The major treatment methods for DME include laser photocoagulation therapy, anti-inflammatory therapy and anti-vascular endothelial growth factor (VEGF) therapy. In recent years, anti-VEGF drugs such as Ranibizumab, Bevacizumab, VEGF-Trap and KH902 have exhibited favorable effects in treatment of DME. The research progress of anti-VEGF therapy for DME is reviewed in this paper, and the efficacy and safety of anti-VEGF therapy are explored.